JO3337B1 - تركيبات صيدلية تشمل أليسبوريفير - Google Patents

تركيبات صيدلية تشمل أليسبوريفير

Info

Publication number
JO3337B1
JO3337B1 JOP/2011/0373A JOP20110373A JO3337B1 JO 3337 B1 JO3337 B1 JO 3337B1 JO P20110373 A JOP20110373 A JO P20110373A JO 3337 B1 JO3337 B1 JO 3337B1
Authority
JO
Jordan
Prior art keywords
alisporivir
pharmaceutical compositions
lipid
provides
based pharmacy
Prior art date
Application number
JOP/2011/0373A
Other languages
English (en)
Inventor
Goncalves Elisabete
Trupp Bjoern
Sutter Bertrand
Thorens Julien
Chabaut Sebastian
Stowasser Frank
Rapp Karin
Original Assignee
Debiopharm Sa
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45346477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3337(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debiopharm Sa, Novartis Ag filed Critical Debiopharm Sa
Application granted granted Critical
Publication of JO3337B1 publication Critical patent/JO3337B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يوفر الاختراع تركيبة صيدلية مبنية على الدهون تشتمل على alisporivir .
JOP/2011/0373A 2010-12-13 2011-12-11 تركيبات صيدلية تشمل أليسبوريفير JO3337B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42249910P 2010-12-13 2010-12-13
IB2011000319 2011-02-18
IB2011000653 2011-03-25

Publications (1)

Publication Number Publication Date
JO3337B1 true JO3337B1 (ar) 2019-03-13

Family

ID=45346477

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0373A JO3337B1 (ar) 2010-12-13 2011-12-11 تركيبات صيدلية تشمل أليسبوريفير

Country Status (34)

Country Link
US (2) US20140005123A1 (ar)
EP (1) EP2651396B1 (ar)
JP (2) JP6259288B2 (ar)
KR (1) KR101928589B1 (ar)
CN (2) CN105125489B (ar)
AR (1) AR084235A1 (ar)
AU (3) AU2011344331A1 (ar)
BR (1) BR112013014606A2 (ar)
CA (1) CA2819167C (ar)
CL (1) CL2013001684A1 (ar)
CO (1) CO6761388A2 (ar)
CY (1) CY1119468T1 (ar)
DK (1) DK2651396T3 (ar)
EC (1) ECSP13012679A (ar)
ES (1) ES2643135T3 (ar)
HR (1) HRP20171485T1 (ar)
HU (1) HUE036784T2 (ar)
IL (1) IL226554A (ar)
JO (1) JO3337B1 (ar)
LT (1) LT2651396T (ar)
MA (1) MA34709B1 (ar)
MX (1) MX351667B (ar)
MY (1) MY165088A (ar)
NZ (1) NZ610950A (ar)
PE (1) PE20140104A1 (ar)
PH (1) PH12013501192A1 (ar)
PL (1) PL2651396T3 (ar)
PT (1) PT2651396T (ar)
RU (1) RU2639482C2 (ar)
SG (2) SG10201509833YA (ar)
SI (1) SI2651396T1 (ar)
TW (1) TWI599368B (ar)
WO (1) WO2012080176A2 (ar)
ZA (1) ZA201303721B (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5868996B2 (ja) 2010-12-13 2016-02-24 アレイ バイオファーマ、インコーポレイテッド ＩＩＩ型受容体チロシンキナーゼ阻害剤としての置換Ｎ−（１Ｈ−インダゾール−４−イル）イミダゾ［１，２−ａ］ピリジン−３−カルボキサミド化合物
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
WO2015008223A1 (en) 2013-07-17 2015-01-22 Novartis Ag Treatment of hepatitis c virus infection with alisporivir and ribavirin
WO2015136455A1 (en) 2014-03-13 2015-09-17 Novartis Ag New treatments of hepatitis c virus infection
AR114930A1 (es) * 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1274354A (fr) 1956-03-10 1961-10-27 Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol
KR0148748B1 (ko) 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
FR2697040B1 (fr) 1992-10-21 1994-12-30 Ind Entreprise Elément de protection contre le bruit et son utilisation.
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
SE504582C2 (sv) 1995-07-06 1997-03-10 Gs Dev Ab Cyklosporinkomposition baserad på en L2-fas
ID25908A (id) 1998-03-06 2000-11-09 Novartis Ag Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida
AU3843999A (en) * 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
USRE40987E1 (en) * 1998-07-01 2009-11-17 Debiopharm S.A. Cyclosporin with improved activity profile
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
GB0001928D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6979672B2 (en) 2002-12-20 2005-12-27 Polichem, S.A. Cyclosporin-based pharmaceutical compositions
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
PT1793844E (pt) * 2004-10-01 2011-03-10 Debiopharm Sa Utilização de [d-meala]3-[etval]4-csa para o tratamento de infecção causada pelo vírus da hepatite c
US7897565B2 (en) 2004-12-23 2011-03-01 Novartis Ag Compositions for HCV treatment
GB0504950D0 (en) 2005-03-10 2005-04-20 Novartis Ag Organic compositions
CA2741829A1 (en) 2008-11-06 2010-05-14 Debio Recherche Pharmaceutique S.A. Cycloundecadepsipeptide compounds and use of said compounds as a medicament
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير

Also Published As

Publication number Publication date
CO6761388A2 (es) 2013-09-30
ZA201303721B (en) 2014-04-30
US20140005123A1 (en) 2014-01-02
CA2819167A1 (en) 2012-06-21
JP2014503520A (ja) 2014-02-13
EP2651396A2 (en) 2013-10-23
CL2013001684A1 (es) 2014-01-10
KR101928589B1 (ko) 2018-12-12
BR112013014606A2 (pt) 2017-06-06
WO2012080176A2 (en) 2012-06-21
RU2013132543A (ru) 2015-01-20
HUE036784T2 (hu) 2018-08-28
CN103282022A (zh) 2013-09-04
CN105125489B (zh) 2019-04-16
WO2012080176A3 (en) 2012-08-09
JP6259288B2 (ja) 2018-01-10
US10188696B2 (en) 2019-01-29
EP2651396B1 (en) 2017-07-12
AU2016201053A1 (en) 2016-03-10
RU2639482C2 (ru) 2017-12-21
AU2016201053B2 (en) 2017-07-13
AU2017245296A1 (en) 2017-11-02
CA2819167C (en) 2019-12-31
PL2651396T3 (pl) 2017-12-29
CN105125489A (zh) 2015-12-09
AR084235A1 (es) 2013-05-02
KR20140018858A (ko) 2014-02-13
NZ610950A (en) 2015-07-31
TWI599368B (zh) 2017-09-21
TW201306859A (zh) 2013-02-16
PH12013501192A1 (en) 2013-07-15
HRP20171485T1 (hr) 2017-11-17
MA34709B1 (fr) 2013-12-03
AU2011344331A1 (en) 2013-07-11
LT2651396T (lt) 2017-09-25
DK2651396T3 (en) 2017-10-23
MX2013006525A (es) 2013-08-01
PT2651396T (pt) 2017-10-18
IL226554A (en) 2017-12-31
SG190894A1 (en) 2013-07-31
MX351667B (es) 2017-10-24
US20160367624A1 (en) 2016-12-22
ECSP13012679A (es) 2013-08-30
JP2018027949A (ja) 2018-02-22
SI2651396T1 (sl) 2017-11-30
PE20140104A1 (es) 2014-02-04
SG10201509833YA (en) 2016-01-28
ES2643135T3 (es) 2017-11-21
CY1119468T1 (el) 2018-03-07
MY165088A (en) 2018-02-28

Similar Documents

Publication Publication Date Title
JOP20180102B1 (ar) مركب صيدلاني
SMT201600350B (it) Composizioni farmaceutiche
BR112014003052A2 (pt) composições farmacêuticas
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
CO6930367A2 (es) Composiciones farmaceúticas
ITTO20110555A1 (it) Dispositivi distributori di bevande illuminati.
HUE040370T2 (hu) Gyógyszerkészítmények
EP2642979A4 (en) PHARMACEUTICAL COMPOSITION
CO6801722A2 (es) Composiciones farmacéuticas
BR112013014612A2 (pt) composições moc
EP2763756A4 (en) BROMFLUORKOHLENSTOFFZUSAMMENSETZUNGEN
CL2014000815A1 (es) Compuestos derivados de 2-metoxibenzamidas insecticidas; composiciones insecticidas.
CY1119468T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν αλισποριβιρη
ITTO20110268A1 (it) Composizione di maquillage.
EP2635307A4 (en) PHARMACEUTICAL COMPOSITIONS
DK2598175T3 (da) Radiofarmaceutiske sammensætninger
IT1399492B1 (it) Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
FR2957060B1 (fr) Distributeur de comprimes.
CL2011000028S1 (es) Envase dispensador
BR112013016029A2 (pt) composição farmacêutica de fosfomicina.
IT1406067B1 (it) Composizioni eudermiche.
BR112013027390A2 (pt) formulação farmacêutica
BR112013025766A2 (pt) composições farmacêuticas de liberação modificada de desvenlafaxina
IN2015KN00386A (ar)
TN2013000218A1 (en) Pharmaceutical compositions comprising alisporivir